Your browser doesn't support javascript.
loading
A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes.
Ando, Hiroyuki; Yoshinaga, Takashi; Yamamoto, Wataru; Asakura, Keiichi; Uda, Takaaki; Taniguchi, Tomohiko; Ojima, Atsuko; Shinkyo, Raku; Kikuchi, Kiyomi; Osada, Tomoharu; Hayashi, Seiji; Kasai, Chieko; Miyamoto, Norimasa; Tashibu, Hiroyuki; Yamazaki, Daiju; Sugiyama, Atsushi; Kanda, Yasunari; Sawada, Kohei; Sekino, Yuko.
Affiliation
  • Ando H; Japan iPS Cardiac Safety Assessment (JiCSA), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan(2); Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan(3); Safety Research Laboratories, Ono Pharmaceutical Co., Ltd., 50-10 Yamagishi, Mikuni-cho, Sakai-sh
  • Yoshinaga T; Japan iPS Cardiac Safety Assessment (JiCSA), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan(2); Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan(3); Biopharmaceutical Assessments Core Function Unit, Medicine Development Center, Eisai Co., Ltd., 5
  • Yamamoto W; Japan iPS Cardiac Safety Assessment (JiCSA), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan(2); Pharmaceutical Development Research Laboratories, Toxicology Research Department, Teijin Pharma Limited, 4-3-2 Asahigaoka, Hino-shi, Tokyo 191-8512, Japan.
  • Asakura K; Japan iPS Cardiac Safety Assessment (JiCSA), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan(2); Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan(3); Discovery Research Labs., Nippon Shinyaku Co., Ltd., 14 Nishinosho-monguchi-cho, Kisshoin, Minami
  • Uda T; Japan iPS Cardiac Safety Assessment (JiCSA), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan(2); Safety Research Laboratories, Ono Pharmaceutical Co., Ltd., 50-10 Yamagishi, Mikuni-cho, Sakai-shi, Fukui 913-8538, Japan.
  • Taniguchi T; Japan iPS Cardiac Safety Assessment (JiCSA), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan(2); Biopharmaceutical Assessments Core Function Unit, Medicine Development Center, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan.
  • Ojima A; Japan iPS Cardiac Safety Assessment (JiCSA), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan(2); Biopharmaceutical Assessments Core Function Unit, Medicine Development Center, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan.
  • Shinkyo R; Biopharmaceutical Assessments Core Function Unit, Medicine Development Center, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan.
  • Kikuchi K; Biopharmaceutical Assessments Core Function Unit, Medicine Development Center, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan.
  • Osada T; Japan iPS Cardiac Safety Assessment (JiCSA), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan(2); Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan(3); Drug Development Service Segment, LSI Medience Corporation, 13-4 Uchikanda 1-chome, Chiyoda-ku, T
  • Hayashi S; Japan iPS Cardiac Safety Assessment (JiCSA), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan(2); Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan(3); Discovery Research Labs., Nippon Shinyaku Co., Ltd., 14 Nishinosho-monguchi-cho, Kisshoin, Minami
  • Kasai C; Japan iPS Cardiac Safety Assessment (JiCSA), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan(2); Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan(3); Drug Safety Research Laboratories, Astellas Pharma Inc., 21, Miyukigaoka, Tsukuba-shi, Ibaraki 30
  • Miyamoto N; Japan iPS Cardiac Safety Assessment (JiCSA), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan(2); Biopharmaceutical Assessments Core Function Unit, Medicine Development Center, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan.
  • Tashibu H; Japan iPS Cardiac Safety Assessment (JiCSA), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan(2); Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan(3); Research Administration Department, Ina Research Inc., 2148-188 Nishiminowa, Ina-shi, Nagano 399-
  • Yamazaki D; Japan iPS Cardiac Safety Assessment (JiCSA), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan(2); Division of Pharmacology, National Institute of Health Sciences (NIHS), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
  • Sugiyama A; Japan iPS Cardiac Safety Assessment (JiCSA), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan(2); Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan(3); Department of Pharmacology, Faculty of Medicine, Toho University, 5-21-16 Omori-nishi, Ota-ku, To
  • Kanda Y; Japan iPS Cardiac Safety Assessment (JiCSA), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan(2); Division of Pharmacology, National Institute of Health Sciences (NIHS), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
  • Sawada K; Japan iPS Cardiac Safety Assessment (JiCSA), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan(2); Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan(3); Biopharmaceutical Assessments Core Function Unit, Medicine Development Center, Eisai Co., Ltd., 5
  • Sekino Y; Japan iPS Cardiac Safety Assessment (JiCSA), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan(2); Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan(3); Division of Pharmacology, National Institute of Health Sciences (NIHS), 1-18-1 Kamiyoga, Setagaya
J Pharmacol Toxicol Methods ; 84: 111-127, 2017.
Article de En | MEDLINE | ID: mdl-27956204
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Potentiels d'action / Torsades de pointes / Myocytes cardiaques / Cardiotoxines / Cellules souches pluripotentes induites Type d'étude: Etiology_studies / Prognostic_studies Limites: Humans Langue: En Journal: J Pharmacol Toxicol Methods Sujet du journal: FARMACOLOGIA / TOXICOLOGIA Année: 2017 Type de document: Article
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Potentiels d'action / Torsades de pointes / Myocytes cardiaques / Cardiotoxines / Cellules souches pluripotentes induites Type d'étude: Etiology_studies / Prognostic_studies Limites: Humans Langue: En Journal: J Pharmacol Toxicol Methods Sujet du journal: FARMACOLOGIA / TOXICOLOGIA Année: 2017 Type de document: Article